Last reviewed · How we verify
sirolimus (drug), mmf (drug)
sirolimus (drug), mmf (drug) is a Immunosuppressive agents (mTOR inhibitor + IMPDH inhibitor combination) Small molecule drug developed by University Hospital Muenster. It is currently FDA-approved for Prevention of organ rejection in solid organ transplantation (kidney, heart, liver), Graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation.
Sirolimus and MMF are immunosuppressive agents that work together to prevent organ rejection by inhibiting T-cell proliferation through different pathways.
Sirolimus and MMF are immunosuppressive agents that work together to prevent organ rejection by inhibiting T-cell proliferation through different pathways. Used for Prevention of organ rejection in solid organ transplantation (kidney, heart, liver), Graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation.
At a glance
| Generic name | sirolimus (drug), mmf (drug) |
|---|---|
| Sponsor | University Hospital Muenster |
| Drug class | Immunosuppressive agents (mTOR inhibitor + IMPDH inhibitor combination) |
| Target | mTOR (sirolimus); IMPDH type II (MMF) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Transplantation |
| Phase | FDA-approved |
Mechanism of action
Sirolimus (rapamycin) is an mTOR inhibitor that blocks T-cell and B-cell proliferation by preventing progression through the cell cycle. Mycophenolate mofetil (MMF) is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH) that preferentially suppresses lymphocyte proliferation. Together, they provide synergistic immunosuppression for transplant rejection prevention.
Approved indications
- Prevention of organ rejection in solid organ transplantation (kidney, heart, liver)
- Graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation
Common side effects
- Infections (bacterial, viral, fungal)
- Thrombocytopenia
- Anemia
- Gastrointestinal disturbances (diarrhea, nausea)
- Hyperlipidemia
- Impaired wound healing
Key clinical trials
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies (PHASE2)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (PHASE3)
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation (PHASE1, PHASE2)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) (PHASE2)
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
- Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia (PHASE2)
- Advancing Transplantation Outcomes in Children (PHASE2)
- Cryopreserved MMUD BM With PTCy for Hematologic Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sirolimus (drug), mmf (drug) CI brief — competitive landscape report
- sirolimus (drug), mmf (drug) updates RSS · CI watch RSS
- University Hospital Muenster portfolio CI
Frequently asked questions about sirolimus (drug), mmf (drug)
What is sirolimus (drug), mmf (drug)?
How does sirolimus (drug), mmf (drug) work?
What is sirolimus (drug), mmf (drug) used for?
Who makes sirolimus (drug), mmf (drug)?
What drug class is sirolimus (drug), mmf (drug) in?
What development phase is sirolimus (drug), mmf (drug) in?
What are the side effects of sirolimus (drug), mmf (drug)?
What does sirolimus (drug), mmf (drug) target?
Related
- Drug class: All Immunosuppressive agents (mTOR inhibitor + IMPDH inhibitor combination) drugs
- Target: All drugs targeting mTOR (sirolimus); IMPDH type II (MMF)
- Manufacturer: University Hospital Muenster — full pipeline
- Therapeutic area: All drugs in Immunology / Transplantation
- Indication: Drugs for Prevention of organ rejection in solid organ transplantation (kidney, heart, liver)
- Indication: Drugs for Graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation
- Compare: sirolimus (drug), mmf (drug) vs similar drugs
- Pricing: sirolimus (drug), mmf (drug) cost, discount & access